Sermorelin is the amidated GHRH(1–29) fragment, investigated as a probe of pituitary responsiveness and in historical pediatric growth studies.
Explore the research profileSubmit an unpaid laboratory order request for manual review. Availability and any pending amounts require confirmation.
Catalog quantities are not assay results.
GHRH(1–29) peptide
Sermorelin corresponds to the first 29 residues of human growth hormone-releasing hormone with an amidated C terminus. It is neither growth hormone itself nor a ghrelin-receptor agonist. Its sequence also differs from modified GHRH analogues, so studies of those molecules are not automatically direct sermorelin evidence.
This reference describes the published literature. Exact supplied form and chemical specifications require product-specific documentation. The studies are linked in Selected literature.
By stimulating the pituitary GHRH receptor, sermorelin promotes endogenous GH secretion. The response depends on available pituitary function and the surrounding endocrine signals. A positive stimulation response measures the capacity of that system to respond; it does not by itself demonstrate sustained growth or another clinical outcome.
A study in children with GH insufficiency or idiopathic short stature compared GHRH(1–29), GHRP-2, and their combination. Differences between groups emphasized physiological context and helped distinguish GHRH-receptor stimulation from the actions of another secretagogue family. [1]
A multicenter open-label study evaluated GHRH(1–29) in previously untreated prepubertal children with GH deficiency. Growth velocity increased during observation. The selected population and lack of a randomized concurrent control limit extrapolation beyond that historical study setting. [2]
A separate study followed short, slowly growing children during and after GHRH(1–29) exposure. Overall growth rates returned toward pretreatment levels after discontinuation, illustrating the difference between an on-study response and a lasting change after exposure ends. [3]
Study topics describe the cited models, not established benefits of this catalog material.
Direct human research exists, including physiological comparisons and longitudinal pediatric studies. These papers answer questions about pituitary responsiveness and growth in selected children. They do not establish benefits for healthy-adult aging, muscle gain, recovery, or broadly defined hormone optimization.
Study era, selection criteria, sample size, and open-label designs matter when weighing the evidence. GHRH fragments require an adequately responsive endocrine system, and results cannot be assumed to match administered GH. The references do not verify the WYZ Labs preparation or make it equivalent to a clinical formulation.
Primary studies and clearly identified supporting sources. Each link opens the original record.
Acute comparative stimulation experiment, not evidence of lasting growth benefit.
Multicenter pediatric study of GHRH(1–29), without a randomized concurrent control.
Follow-up distinguishes growth during exposure from outcomes after discontinuation.
Literature reviewed October 2026. This is a selected research overview, not an exhaustive systematic review. Published findings do not establish the identity, purity, sterility or suitability of any WYZ batch. For laboratory research only; not for human or veterinary use.
Final product specifications and product-specific storage instructions have not been supplied. Review the original documentation and your laboratory’s procedures before obtaining or using the material.
For qualified laboratory researchers. Not for human or veterinary use. Product information is not medical advice or a recommendation for personal use.
What to look for in a COAOther single compounds in the collection.
Metabolic Research
Retatrutide is a synthetic peptide studied for coordinated activation of three metabolic hormone receptors, with human research examining glucose regulation, appetite, body weight and liver fat.
Metabolic Research
MOTS-c is a mitochondrial-derived peptide studied in metabolic signaling and skeletal-muscle adaptation, with experimental interventions supported mainly by cell and animal evidence.
Dermal Research
GHK-Cu is a copper complex of glycyl-histidyl-lysine studied for its effects on extracellular-matrix production and remodeling in experimental tissue-repair systems.
